Constellation Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Constellation Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$342K	Buy	4,150 +75	+2%	+$6.1K	0.06%	313
2015 Q4	$427K	Buy	4,075 +50	+1%	+$5.22K	0.08%	265
2015 Q3	$424K	Buy	+4,025	New	+$538K	0.09%	253

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Constellation Investments's BMRN Position: Q1 2016 in Review

Constellation Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 1.8% in Q1 2016, buying an estimated $6.1K and bringing the position to 4,150 shares worth $342K. The position accounts for 0.06% of the portfolio, ranked #313.

Constellation Investments first reported a position in BMRN in Q3 2015 and has held it in 3 quarters since. The position peaked at $427K in Q4 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Constellation Investments held 4,150 shares of BioMarin Pharmaceuticals worth $342K as of Q1 2016.
Constellation Investments bought 75 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $6.1K.
BioMarin Pharmaceuticals made up 0.06% of Constellation Investments's portfolio in Q1 2016, its #313 holding.
Constellation Investments first reported a position in BioMarin Pharmaceuticals in Q3 2015 and has held it in 3 quarters since.
Constellation Investments's BioMarin Pharmaceuticals position peaked at $427K in Q4 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Constellation Investments's 13F filing for Q1 2016, filed 28 Apr 2016.